Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Non-cash Items (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Non-cash Items for 3 consecutive years, with $36.6 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 6221.24% to $36.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.6 million through Dec 2025, up 6221.24% year-over-year, with the annual reading at $36.6 million for FY2025, 6221.24% up from the prior year.
  • Non-cash Items hit $36.6 million in Q4 2025 for Compass Therapeutics, up from $11.6 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $36.6 million in Q4 2025 to a low of $11000.0 in Q4 2023.
  • Historically, Non-cash Items has averaged $9.6 million across 3 years, with a median of $10.4 million in 2023.
  • Biggest five-year swings in Non-cash Items: tumbled 82.69% in 2024 and later soared 6221.24% in 2025.
  • Year by year, Non-cash Items stood at $11000.0 in 2023, then skyrocketed by 5163.64% to $579000.0 in 2024, then skyrocketed by 6221.24% to $36.6 million in 2025.
  • Business Quant data shows Non-cash Items for CMPX at $36.6 million in Q4 2025, $11.6 million in Q3 2025, and $19.5 million in Q2 2025.